Bob Simpson
About Bob Simpson
Bob Simpson is an Associate Director at Venatorx Pharmaceuticals Inc., with a strong background in pharmaceuticals and a focus on small molecule drug development. He holds degrees from prestigious institutions including Harvard Medical School and has extensive experience in various roles within the industry.
Current Role at Venatorx Pharmaceuticals
Bob Simpson serves as Associate Director at Venatorx Pharmaceuticals Inc. since 2017. His role involves overseeing various aspects of pharmaceutical development in Malvern, Pennsylvania. He contributes to the company's mission of advancing innovative therapies, leveraging his extensive background in the pharmaceuticals industry.
Education and Expertise
Bob Simpson has a robust educational background in the sciences. He studied at Case Western Reserve University and Harvard Medical School, furthering his expertise in the field. He earned a Master's degree in Pharmacy from Temple University, focusing on Pharmacy Administration and Pharmacy Policy and Regulatory Affairs. Additionally, he holds a Doctorate in Chemistry from the University of California, Berkeley, which enhances his research capabilities in drug development.
Previous Experience in Pharmaceuticals
Prior to his current position, Bob Simpson held several roles in the pharmaceuticals sector. He worked as a Research Chemist at Dupont from 1994 to 2000, followed by a position as Senior Scientist at Boehringer Ingelheim from 2000 to 2002. He then joined Vitae Pharmaceuticals as a Fellow, where he contributed for 14 years until 2017. His diverse experiences have equipped him with a comprehensive understanding of the industry.
Research Background and Skills
Bob Simpson has a strong research background in small molecule drug development. His expertise encompasses Good Manufacturing Practices (GMP), Process Research and Development, Organic Synthesis, Drug Discovery, and Regulatory Documentation Preparation. This skill set supports his contributions to pharmaceutical projects and regulatory compliance.